Lajos Pusztai, MD, DPhil, discusses key takeaways from analysis of the KEYNOTE-522 clinical trial of pembrolizumab plus chemotherapy in the neoadjuvant or adjuvant setting for patients with triple-negative breast cancer.
- August 22, 2022
The Breast Cancer Research Foundation (BCRF) Scientific Advisory Board and its Board of Directors recently announced its 2022 research grants, including six funded grants at Yale Cancer Center and Smilow Cancer Hospital awarded to Mehra Golshan, MD, MBA, Melinda Irwin, PhD, MPH, Ian Krop, MD, PhD, Lajos Pusztai, MD, DPhil, David Rimm, MD, PhD, and Eric Winer, MD to support their research.
- July 29, 2022
Benefits of Pre-surgical Immunotherapy Were Independent of Race in Patients with Aggressive Breast CancerSource: AACR
Treatment outcomes were similar between Black and non-Black patients with triple-negative breast cancer who received neoadjuvant durvalumab (Imfinzi) plus chemotherapy, according to phase I/II clinical trial results published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
- June 16, 2022Source: Targeted Oncology
Lajos Pusztai, MD, DPhil, discusses multiple analyses of the phase 3 KEYNOTE-522 clinical trial of pembrolizumab plus chemotherapy administered in the neoadjuvant or adjuvant setting to patients with triple-negative breast cancer versus placebo plus chemotherapy.
- June 03, 2022Source: The Sun
Cancer patients should be prescribed fitness classes and workouts to boost their survival, doctors say. Patients should try to do both muscle strengthening work and cardio exercises such as swimming - and even simple chores like gardening or carrying heavy shopping could improve health.
- April 29, 2022Source: OncologyTube
Lajos Pusztai, MD, DPhil speaks about the Cancer Relevance of Human Genes.
- April 25, 2022Source: Bio News
More human genes have been identified as driving cancer development than previously assumed. The study evaluated 12,767 human genes that interact, directly or indirectly, with certain core cancer genes, which are known to have a significant impact on the development of cancer.
- April 15, 2022Source: ASCO Post
Following an analysis of over 12,000 human genes, research from Yale Cancer Center indicates there is cancer-relevant importance in a much larger proportion of human genes than current cancer research models suggest.
- April 14, 2022
Following an analysis of over 12,000 human genes, research from Yale Cancer Center indicates there is cancer-relevant importance in a much larger proportion of human genes than current cancer research models suggest. Much of cancer biology research focuses on a few dozen well studied genes called “cancer driver genes.” The new findings demonstrate that a larger number of genes are connected to cancer driver genes and may have an impact on cancer biology. The findings were published in the Journal of the National Cancer Institute.
- December 09, 2021
New research led by Yale Cancer Center reveals young women with breast cancer and a family history of the disease, but no high penetrance germline mutations, have an increased number of rare germline variants in cancer-relevant genes.